mProX™ Human BRAF Stable Cell Line

Product Information

Target Protein

BRAF

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

RKO; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cardiovascular Research; Cancer Research; Reproductive Research

Related Diseases

Cardiofaciocutaneous Syndrome 1 and Lung Cancer. Among its related pathways are IL-9 Signaling Pathways and Prolactin Signaling

Gene ID

673

UniProt ID

P15056

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The human gene BRAF produces the B-Raf protein. The protein is officially recognized as serine/threonine-protein kinase B-Raf, however the gene is also known as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B. The B-Raf protein is engaged in intracellular signaling that controls the proliferation of cells. Birth abnormalities are caused by certain other hereditary BRAF mutations. Cell division, differentiation, and secretion are impacted by the MAP kinase/ERKs signaling pathway, which is regulated by this protein. The customized BRAF stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Matthew

I recently purchased the human BRAF overexpression cell line, and it has exceeded my expectations. Apr 26 2023

chat Verified Customer

chat Anthony

We are delighted with the versatility and efficiency of BRAF cell line as a research tool. Mar 22 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Generation and validation of BRAF knockout cell lines.

Limiting dilution was used to create a single clone from the parental colorectal cancer cell line RKO. Following infection with the AAV-BRAF-Hyg virus, the first oncogenically mutated allele (onc) was eliminated, and the RKO-derived clone BRAF-/onc/wt, or RBOW, cell line, was created.

Ref: Hirschi, Benjamin, et al. "Genetic targeting of B-Raf V600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells." Molecular Cancer 13 (2014): 1-12.

Pubmed: 24885690

DOI: 10.1186/1476-4598-13-122

Research Highlights

The RAS-RAF-MEK-ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients carry a druggable hotspot V600E/K mutation in the BRAF protein kinase.
Dankner, Matthew, et al. "Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations." Oncogene 37.24 (2018): 3183-3199.
Pubmed: 29540830 DOI: 10.1038/s41388-018-0171-x

According to this study, the triple-combination therapy may increase the frequency of long-lasting anticancer responses, which may be beneficial for a subset of patients with metastatic melanoma that has a BRAFV600 mutation.
Ribas, Antoni, et al. "Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma." Nature medicine 25.6 (2019): 936-940.
Pubmed: 31171879 DOI: 10.1038/s41591-019-0476-5